the delay is the rarity of the disease and the need for more information to develop the right endpoints for trials. best to be as informed as possible to accurately pinpoint all the effects of MSA on patients so that we can see how 434 affects function in all of these areas and thus measure the benefit to patients overall.
Ann: New Publication Demonstrates ATH434 is Neuroprotective, page-5
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.60M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $20 | 4.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 77506128 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 37863632 | 25 |
View Market Depth
| Last trade - 10.38am 26/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |